Open Access

REVIEW

A Holistic Review of Oncological Drug Targets and Trajectories of Resistance in Cancer Therapy

Harpreet Kaur^1,*, Dhrubalochan Rana², Sowvik Bag², Paramjeet Singh³

1 University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India
2 M. M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, 133207, India
3 Aurobindo Pharma, Durham, NC 27709, USA

* Corresponding Author: Harpreet Kaur. Email:

(This article belongs to the Special Issue: Drug Targets in Oncology: Mechanisms, Challenges, and Innovations)

Oncology Research 2026, 34(2), 5 https://doi.org/10.32604/or.2025.071209

Received 02 August 2025; Accepted 11 December 2025; Issue published 19 January 2026

Abstract

The prolonged and intricate history of oncological treatments has transitioned significantly since the introduction of chemotherapy. Substantial therapeutic benefits in cancer therapy have been achieved by the integration of conventional treatments with molecular biosciences and omics technologies. Human epidermal growth factor receptor, hormone receptors, and angiogenesis factors are among the established therapies in tumor reduction and managing side effects. Novel targeted therapies like KRAS G12C, Claudin-18 isoform 2 (CLDN18.2), Trophoblast cell-surface antigen 2 (TROP2), and epigenetic regulators emphasize their promise in advancing precision medicine. However, in many cases, the resistance mechanisms associated with these interventions render them ineffective in carrying out their functions. The purpose of this review is to provide a comprehensive and up-to-date examination of both established and emerging drug targets and mechanisms of treatment resistance in oncology. This review seeks to elucidate recent advancements, address persisting challenges, and explore opportunities for innovative developments in cancer target research. Additionally, it explores the growing role of artificial intelligence in reshaping cancer drug discovery and development frameworks as potential avenues for future research. In conclusion, innovative approaches in oncology, supported by pharmacological research, ongoing clinical trials, molecular biosciences, and artificial intelligence, are poised to significantly transform cancer treatment.

---

Graphic Abstract

---

Keywords

---